FDA Accepts Verastem NDA for Priority Review, Stocks Up 20% (Update)

Grandbrothers Verastem (NASDAQ:VSTM) shares rose 20% in after-hours trading on news that the FDA accepted for priority review the company's new drug application for accelerated approval of its ovarian cancer drugs avutometinib and defactinib, with Source link